NAV

Bisantrene

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bisantrene
DrugBank Accession Number
DB17247
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 398.474
Monoisotopic: 398.19674274
Chemical Formula
C22H22N8
Synonyms
  • 9,10-anthracenedicarboxaldehyde bis(2-imidazolin-2-ylhydrazone)
  • 9,10-anthracenedicarboxaldehyde, bis((4,5-dihydro-1h-imidazol-2-yl)hydrazone)
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Bisantrene hydrochloride74GNV897RO71439-68-4Not applicable

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
39C34M111K
CAS number
78186-34-2
InChI Key
NJSMWLQOCQIOPE-OCHFTUDZSA-N
InChI
InChI=1S/C22H22N8/c1-2-6-16-15(5-1)19(13-27-29-21-23-9-10-24-21)17-7-3-4-8-18(17)20(16)14-28-30-22-25-11-12-26-22/h1-8,13-14H,9-12H2,(H2,23,24,29)(H2,25,26,30)/b27-13+,28-14+
IUPAC Name
2-[(2E)-2-({10-[(E)-[2-(4,5-dihydro-1H-imidazol-2-yl)hydrazin-1-ylidene]methyl]anthracen-9-yl}methylidene)hydrazin-1-yl]-4,5-dihydro-1H-imidazole
SMILES
C1CN=C(N\N=C\C2=C3C=CC=CC3=C(\C=N\NC3=NCCN3)C3=C2C=CC=C3)N1

References

General References
Not Available
ChemSpider
4508346
ChEMBL
CHEMBL25336
ZINC
ZINC000001577736
Wikipedia
Bisantrene

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAcute Myeloid Leukemia / Allogeneic Stem Cell Transplantation1
2RecruitingTreatmentAcute Myeloid Leukemia1
1WithdrawnTreatmentAcute Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Higher Risk Myelodysplastic Syndrome (MDS) / Recurrent Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia (AML)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0265 mg/mLALOGPS
logP1.24ALOGPS
logP2.6Chemaxon
logS-4.2ALOGPS
pKa (Strongest Acidic)16.83Chemaxon
pKa (Strongest Basic)6.21Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area97.56 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity140.32 m3·mol-1Chemaxon
Polarizability44.44 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at November 30, 2022 17:08 / Updated at December 13, 2022 10:46